PPARG and Alzheimer disease: Overall, this study showed significant dysregulation of SPMs and an attempt at inflammation resolution to compensate for the pro-inflammatory environment by increasing SPM receptors, an SPM biosynthetic enzyme (15-LOX2) and PPARγ in the AD brain.